TimesSquare Capital Management LLC trimmed its holdings in shares of Quotient Limited (NASDAQ:QTNT) by 6.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,543,671 shares of the company’s stock after selling 249,000 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Quotient were worth $13,041,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Quotient by 102.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,767 shares of the company’s stock worth $61,000 after purchasing an additional 5,961 shares in the last quarter. Citigroup Inc. increased its stake in Quotient by 81.3% during the 4th quarter. Citigroup Inc. now owns 14,715 shares of the company’s stock worth $77,000 after purchasing an additional 6,599 shares in the last quarter. ProShare Advisors LLC bought a new stake in Quotient during the 4th quarter worth approximately $84,000. Principal Financial Group Inc. bought a new stake in Quotient during the 4th quarter worth approximately $96,000. Finally, Squarepoint Ops LLC increased its stake in Quotient by 63.4% during the 4th quarter. Squarepoint Ops LLC now owns 19,706 shares of the company’s stock worth $103,000 after purchasing an additional 7,648 shares in the last quarter. 80.09% of the stock is owned by institutional investors and hedge funds.
NASDAQ:QTNT opened at $4.40 on Friday. Quotient Limited has a twelve month low of $3.41 and a twelve month high of $8.77. The company has a current ratio of 3.33, a quick ratio of 2.86 and a debt-to-equity ratio of 17.75. The business’s 50 day moving average price is $3.96. The firm has a market cap of $446.72 million, a P/E ratio of -4.00 and a beta of 2.32.
Separately, The Goldman Sachs Group assumed coverage on Quotient in a research note on Thursday, June 3rd. They set a “neutral” rating and a $5.00 target price for the company.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening.
Recommended Story: Put Option Volume
Want to see what other hedge funds are holding QTNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quotient Limited (NASDAQ:QTNT).
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.